Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Chronic kidney disease and prior MI were each present in 28.6% ( n = 8)
Stir until fully dissolved and drink immediately
Appetite or weight changes reported by some users, although Melanotan II is not an approved weight-loss treatment
Retatrutide (2026) Semaglutide Mechanism: GLP-1 receptor agonist FDA Status: Approved for diabetes and weight management Expected Weight Loss: 1520% body weight Administration: Weekly injection Onset: Appetite changes within first few weeks Cost: Membership pricing at Better Med Spa see plans Tirzepatide Mechanism: Dual GIP + GLP-1 receptor agonist FDA Status: Approved for diabetes and weight management Expected Weight Loss: Up to 22% body weight Administration: Weekly injection Onset: Often faster appetite suppression Cost: Membership pricing at Better Med Spa see plans Retatrutide Mechanism: Triple agonist (GLP-1 + GIP + Glucagon) FDA Status: NOT approved investigational only Expected Weight Loss: Early data suggests very potent effects (up to 24% in trials) Administration: Weekly injection (investigational protocols) Onset: Under investigation Cost: Not yet available What Are Semaglutide, Tirzepatide, and Retatrutide
Preclinical studies indicate that Dihexa binds to HGF with picomolar affinity, stabilizing the active dimeric conformation required to phosphorylate the c-Met receptor
US$ 25.19
US$ 26.91
US$ 27.60
US$ 27.89
US$ 20.34
US$ 21.19
US$ 21.72
US$ 23.79
US$ 25.94
US$ 26.08
